-
1
-
-
0001869668
-
Cancer chemopreventive agents. Drug development status and future prospects
-
Keloff, G.J., Boone, C.W. Cancer chemopreventive agents. Drug development status and future prospects. J. Cell. Biochem. 1994;20:1-103.
-
(1994)
J. Cell. Biochem
, vol.20
, pp. 1-103
-
-
Keloff, G.J.1
Boone, C.W.2
-
2
-
-
79952232216
-
Global cancer statistics
-
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
-
(2011)
CA Cancer J Clin
, vol.61
, pp. 69-90
-
-
Jemal, A.1
Bray, F.2
Center, M.M.3
Ferlay, J.4
Ward, E.5
Forman, D.6
-
3
-
-
0025312728
-
A genetic model for colorectal tumorigenesis
-
Fearon ER, Vogelstein BA. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759-67.
-
(1990)
Cell
, vol.61
, pp. 759-767
-
-
Fearon, E.R.1
Vogelstein, B.A.2
-
4
-
-
84857392643
-
Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths
-
Zauber AG, Winawer SJ, O'Brien MJ, Lansdorp-Vogelaar I, van Ballegooijen M, Hankey BF, et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med. 2012;366(8):687-96.
-
(2012)
N Engl J Med
, vol.366
, Issue.8
, pp. 687-696
-
-
Zauber, A.G.1
Winawer, S.J.2
O'Brien, M.J.3
Lansdorp-Vogelaar, I.4
Van Ballegooijen, M.5
Hankey, B.F.6
-
5
-
-
0027731797
-
Prevention of colorectal cancer by colonoscopic polypectomy
-
DOI 10.1056/NEJM199312303292701
-
Winawer SJ, Zauber AG, Ho MN, O'Brien MJ, Gottlieb LS, Sternberg SS, et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med. 1993;329(27):1977-81. (Pubitemid 24015040)
-
(1993)
New England Journal of Medicine
, vol.329
, Issue.27
, pp. 1977-1981
-
-
Winawer, S.J.1
Zauber, A.G.2
May, N.H.3
O'Brien, M.J.4
Gottlieb, L.S.5
Sternberg, S.S.6
Waye, J.D.7
Schapiro, M.8
Bond, J.H.9
Panish, J.F.10
Ackroyd, F.11
Shike, M.12
Kurtz, R.C.13
Hornsby-Lewis, L.14
Gerdes, H.15
Stewart, E.T.16
Lightdale, C.J.17
Edelman, M.18
Fleisher, M.19
-
6
-
-
41349104451
-
Chemoprevention of colorectal neoplasia: The potential for personalized medicine
-
DOI 10.1053/j.gastro.2008.02.012, PII S0016508508002436
-
Arber N, Levin B. Chemoprevention of colorectal neoplasia: the potential for personalized medicine. Gastroenterology. 2008;134:1224-37. (Pubitemid 351451998)
-
(2008)
Gastroenterology
, vol.134
, Issue.4
, pp. 1224-1237
-
-
Arber, N.1
Levin, B.2
-
7
-
-
83955161674
-
Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: An analysis from the CAPP2 randomised controlled trial
-
Burn J, Gerdes AM, Macrae F, Mecklin JP, Moeslein G, Olschwang S, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet. 2011;378(9809):2081-7.
-
(2011)
Lancet
, vol.378
, Issue.9809
, pp. 2081-2087
-
-
Burn, J.1
Gerdes, A.M.2
Macrae, F.3
Mecklin, J.P.4
Moeslein, G.5
Olschwang, S.6
-
9
-
-
33748180713
-
Celecoxib for prevention of colorectal adenomas
-
Arber N, Eagle CJ, Spicak J, et al. Celecoxib for prevention of colorectal adenomas. N Engl J Med. 2006;355:885-95.
-
(2006)
N Engl J Med
, vol.355
, pp. 885-895
-
-
Arber, N.1
Eagle, C.J.2
Spicak, J.3
-
10
-
-
33748196958
-
Celecoxib for the prevention of sporadic colorectal adenomas
-
DOI 10.1056/NEJMoa061355
-
Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006;355:873-84. (Pubitemid 44315980)
-
(2006)
New England Journal of Medicine
, vol.355
, Issue.9
, pp. 873-884
-
-
Bertagnolli, M.M.1
Eagle, C.J.2
Zauber, A.G.3
Redston, M.4
Solomon, S.D.5
Kim, K.6
Tang, J.7
Rosenstein, R.B.8
Wittes, J.9
Corle, D.10
Hess, T.M.11
Woloj, G.M.12
Boisserie, F.13
Anderson, W.F.14
Viner, J.L.15
Bagheri, D.16
Burn, J.17
Chung, D.C.18
Dewar, T.19
Foley, T.R.20
Hoffman, N.21
Macrae, F.22
Pruitt, R.E.23
Saltzman, J.R.24
Salzberg, B.25
Sylwestrowicz, T.26
Gordon, G.B.27
Hawk, E.T.28
more..
-
11
-
-
33845288081
-
A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas
-
DOI 10.1053/j.gastro.2006.08.079, PII S0016508506019949
-
Baron JA, Sandler RS, Bresalier RS, et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology. 2006;131:1674-82. (Pubitemid 44958508)
-
(2006)
Gastroenterology
, vol.131
, Issue.6
, pp. 1674-1682
-
-
Baron, J.A.1
Sandler, R.S.2
Bresalier, R.S.3
Quan, H.4
Riddell, R.5
Lanas, A.6
Bolognese, J.A.7
Oxenius, B.8
Horgan, K.9
Loftus, S.10
Morton, D.G.11
-
12
-
-
42449093389
-
Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: The cross trial safety analysis
-
DOI 10.1161/CIRCULATIONAHA.108.764530, PII 0000301720080422000011
-
Solomon SD, Wittes J, Finn PV, et al. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation. 2008;117:2104-13. (Pubitemid 351572169)
-
(2008)
Circulation
, vol.117
, Issue.16
, pp. 2104-2113
-
-
Solomon, S.D.1
Wittes, J.2
Finn, P.V.3
Fowler, R.4
Viner, J.5
Bertagnolli, M.M.6
Arber, N.7
Levin, B.8
Meinert, C.L.9
Martin, B.10
Pater, J.L.11
Goss, P.E.12
Lance, P.13
Obara, S.14
Chew, E.Y.15
Kim, J.16
Arndt, G.17
Hawk, E.18
-
13
-
-
78650215449
-
Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials
-
Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, Warlow CP, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010;376(9754):1741-50.
-
(2010)
Lancet
, vol.376
, Issue.9754
, pp. 1741-1750
-
-
Rothwell, P.M.1
Wilson, M.2
Elwin, C.E.3
Norrving, B.4
Algra, A.5
Warlow, C.P.6
-
14
-
-
84863412124
-
Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: Analysis of the time course of risks and benefits in 51 randomised controlled trials
-
Rothwell PM, Price JF, Fowkes FG, Zanchetti A, Roncaglioni MC, Tognoni G, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet. 2012;379(9826):1602-12.
-
(2012)
Lancet
, vol.379
, Issue.9826
, pp. 1602-1612
-
-
Rothwell, P.M.1
Price, J.F.2
Fowkes, F.G.3
Zanchetti, A.4
Roncaglioni, M.C.5
Tognoni, G.6
-
15
-
-
84855556537
-
Aspirin in the chemoprevention of colorectal neoplasia: An overview
-
Chan AT, Arber N, Burn J, et al. Aspirin in the chemoprevention of colorectal neoplasia: an overview. Cancer Prev Res (Phila). 2012;5:164-78.
-
(2012)
Cancer Prev Res (Phila)
, vol.5
, pp. 164-178
-
-
Chan, A.T.1
Arber, N.2
Burn, J.3
-
16
-
-
84867817838
-
Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival
-
Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med. 2012;367(17):1596-606.
-
(2012)
N Engl J Med
, vol.367
, Issue.17
, pp. 1596-1606
-
-
Liao, X.1
Lochhead, P.2
Nishihara, R.3
Morikawa, T.4
Kuchiba, A.5
Yamauchi, M.6
-
17
-
-
79952232216
-
Global cancer statistics
-
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
-
(2011)
CA Cancer J Clin
, vol.61
, Issue.2
, pp. 69-90
-
-
Jemal, A.1
Bray, F.2
Center, M.M.3
Ferlay, J.4
Ward, E.5
Forman, D.6
-
19
-
-
0036179267
-
Epidemiological differences between adenocarcinoma of the oesophagus and adenocarcinoma of the gastric cardia in the USA
-
DOI 10.1136/gut.50.3.368
-
El-Serag HB, Mason AC, Petersen N, Key CR. Epidemiological differences between adenocarcinoma of the oesophagus and adenocarcinoma of the gastric cardia in the USA. Gut. 2002;50(3):368-72. (Pubitemid 34161053)
-
(2002)
Gut
, vol.50
, Issue.3
, pp. 368-372
-
-
El-Serag, H.B.1
Mason, A.C.2
Petersen, N.3
Key, C.R.4
-
20
-
-
73549083853
-
Clinical practice. Barrett's esophagus
-
Sharma P. Clinical practice. Barrett's esophagus. N Engl J Med. 2009;361:2548-56.
-
(2009)
N Engl J Med
, vol.361
, pp. 2548-2556
-
-
Sharma, P.1
-
21
-
-
0036179390
-
Surveillance and survival in Barrett's adenocarcinomas: A population-based study
-
Corley DA, Levin TR, Habel LA, Weiss NS, Buffler PA. Surveillance and survival in Barrett's adenocarcinomas: a populationbased study. Gastroenterology. 2002;122:633-40. (Pubitemid 34173814)
-
(2002)
Gastroenterology
, vol.122
, Issue.3
, pp. 633-640
-
-
Corley, D.A.1
Levin, T.R.2
Habel, L.A.3
Weiss, N.S.4
Buffler, P.A.5
-
22
-
-
0037418145
-
Screening and surveillance for Barrett esophagus in high-risk groups: A cost-utility analysis
-
Inadomi JM, Sampliner R, Lagergren J, Lieberman D, Fendrick AM, Vakil N. Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis. Ann Intern Med. 2003;138:176-86. (Pubitemid 36231623)
-
(2003)
Annals of Internal Medicine
, vol.138
, Issue.3
, pp. 176-186
-
-
Inadomi, J.M.1
Sampliner, R.2
Lagergren, J.3
Lieberman, D.4
Fendrick, A.M.5
Vakil, N.6
-
23
-
-
79952288119
-
American gastroenterological association medical position statement on the management of Barrett's esophagus
-
Spechler SJ. American gastroenterological association medical position statement on the management of Barrett's esophagus. Gastroenterology. 2011;140:1084-91.
-
(2011)
Gastroenterology
, vol.140
, pp. 1084-1091
-
-
Spechler, S.J.1
-
24
-
-
84875365855
-
Proton pump inhibitors reduce the risk of neoplastic progression in patients with barrett's esophagus
-
Accepted for publication
-
Kastelein F, Spaander MCW, Steyerberg EW. Proton pump inhibitors reduce the risk of neoplastic progression in patients with barrett's esophagus. Clin Gastroenterol Hepatol. 2013 Accepted for publication.
-
(2013)
Clin Gastroenterol Hepatol
-
-
Kastelein, F.1
Spaander, M.C.W.2
Steyerberg, E.W.3
-
25
-
-
81355160270
-
Systematic review: The use of proton pump inhibitors and increased susceptibility to enteric infection
-
Bavishi C, DuPont HL. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther. 2011;34:1269-81.
-
(2011)
Aliment Pharmacol Ther
, vol.34
, pp. 1269-1281
-
-
Bavishi, C.1
Dupont, H.L.2
-
26
-
-
80455173556
-
Host and pathogen factors for Clostridium difficile infection and colonization
-
Loo VG, Bourgault AM, Poirier L, Lamothe F, Michaud S, Turgeon N, et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med. 2011;365(18):1693-703.
-
(2011)
N Engl J Med
, vol.365
, Issue.18
, pp. 1693-1703
-
-
Loo, V.G.1
Bourgault, A.M.2
Poirier, L.3
Lamothe, F.4
Michaud, S.5
Turgeon, N.6
-
27
-
-
77952837521
-
Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus
-
Nguyen DM, Richardson P, El-Serag HB. Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. Gastroenterology. 2010;138:2260-6.
-
(2010)
Gastroenterology
, vol.138
, pp. 2260-2266
-
-
Nguyen, D.M.1
Richardson, P.2
El-Serag, H.B.3
-
28
-
-
0037219463
-
Protective association of aspirin/NSAIDs and esophageal cancer: A systematic review and meta-analysis
-
DOI 10.1053/gast.2003.50008
-
Corley DA, Kerlikowske K, Verma R, et al. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology. 2003;124:47-56. (Pubitemid 36055338)
-
(2003)
Gastroenterology
, vol.124
, Issue.1
, pp. 47-56
-
-
Corley, D.A.1
Kerlikowse, K.2
Verma, R.3
Buffler, P.4
-
29
-
-
28044459843
-
Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: A prospective study
-
DOI 10.1016/S1470-2045(05)70431-9, PII S1470204505704319
-
Vaughan TL, Dong LM, Blount PL, et al. Non-steroidal antiinflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study. Lancet Oncol. 2005;6:945-52. (Pubitemid 41685227)
-
(2005)
Lancet Oncology
, vol.6
, Issue.12
, pp. 945-952
-
-
Vaughan, T.L.1
Dong, L.M.2
Blount, P.L.3
Ayub, K.4
Odze, R.D.5
Sanchez, C.A.6
Rabinovitch, P.S.7
Reid, B.J.8
-
30
-
-
33646436171
-
Nonsteroidal antiinflammatory drugs and the esophageal inflammationmetaplasiaadenocarcinoma sequence
-
Anderson LA, Johnston BT, Watson RG, et al. Nonsteroidal antiinflammatory drugs and the esophageal inflammationmetaplasiaadenocarcinoma sequence. Cancer Res. 2006;66:4975-82.
-
(2006)
Cancer Res
, vol.66
, pp. 4975-4982
-
-
Anderson, L.A.1
Johnston, B.T.2
Watson, R.G.3
-
32
-
-
0037139613
-
The effect of selective cyclooxygenase-2 inhibition in Barrett's esophagus epithelium: An in vitro study
-
Buttar NS, Wang KK, Anderson MA, et al. The effect of selective cyclooxygenase-2 inhibition in Barrett's esophagus epithelium: an in vitro study. J Natl Cancer Inst. 2002;94:422-9. (Pubitemid 34285091)
-
(2002)
Journal of the National Cancer Institute
, vol.94
, Issue.6
, pp. 422-429
-
-
Buttar, N.S.1
Wang, K.K.2
Anderson, M.A.3
Dierkhising, R.A.4
Pacifico, R.J.5
Krishnadath, K.K.6
Lutzke, L.S.7
-
33
-
-
0029092874
-
Aspirin and reduced risk of esophageal carcinoma
-
Ellen M, Funkhouser PH, Gerald B, Sharp PH. Aspirin and reduced risk of esophageal carcinoma. Cancer. 1995;76(7):1116-9.
-
(1995)
Cancer
, vol.76
, Issue.7
, pp. 1116-1119
-
-
Ellen, M.1
Funkhouser, P.H.2
Gerald, B.3
Sharp, P.H.4
-
34
-
-
84866682144
-
A combination of esomeprazole and aspirin reduces tissue concentrations of prostaglandin E2 in patients with Barrett's esophagus
-
Falk GW, Buttar NS, Foster NR, Ziegler KL, Demars CJ, Romero Y, et al. A combination of esomeprazole and aspirin reduces tissue concentrations of prostaglandin E2 in patients with Barrett's esophagus. Gastroenterology. 2012;143:917-26.
-
(2012)
Gastroenterology
, vol.143
, pp. 917-926
-
-
Falk, G.W.1
Buttar, N.S.2
Foster, N.R.3
Ziegler, K.L.4
Demars, C.J.5
Romero, Y.6
-
35
-
-
0027512524
-
Aspirin use and risk of fatal cancer
-
Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath Jr CW. Aspirin use and risk of fatal cancer. Cancer Res. 1993;53:1322-7. (Pubitemid 23097110)
-
(1993)
Cancer Research
, vol.53
, Issue.6
, pp. 1322-1327
-
-
Thun, M.J.1
Namboodiri, M.M.2
Calle, E.E.3
Flanders, W.D.4
Heath Jr., C.W.5
-
36
-
-
81855167480
-
Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus
-
Kastelein F, Spaander MC, Biermann K, Steyerberg EW, Kuipers EJ, Bruno MJ, et al. Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus. Gastroenterology. 2011;141(6):2000-8.
-
(2011)
Gastroenterology
, vol.141
, Issue.6
, pp. 2000-2008
-
-
Kastelein, F.1
Spaander, M.C.2
Biermann, K.3
Steyerberg, E.W.4
Kuipers, E.J.5
Bruno, M.J.6
-
37
-
-
70849132813
-
Medication usage and the risk of neoplasia in patients with Barrett's esophagus
-
Nguyen DM, El-Serag HB, Henderson L, Stein D, Bhattacharyya A, Sampliner RE. Medication usage and the risk of neoplasia in patients with Barrett's esophagus. Clin Gastroenterol Hepatol. 2009;7:1299-304.
-
(2009)
Clin Gastroenterol Hepatol
, vol.7
, pp. 1299-1304
-
-
Nguyen, D.M.1
El-Serag, H.B.2
Henderson, L.3
Stein, D.4
Bhattacharyya, A.5
Sampliner, R.E.6
-
38
-
-
33750627697
-
Statins and cancer risk: A literature-based meta-analysis and meta-regression analysis of 35 randomized controlled trials
-
DOI 10.1200/JCO.2006.06.3560
-
Bonovas S, Filioussi K, Tsavaris N, Sitaras NM. Statins and cancer risk: a literature-based meta-analysis and meta-regression analysis of 35 randomized controlled trials. J Clin Oncol. 2006;24:4808-17. (Pubitemid 46655612)
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.30
, pp. 4808-4817
-
-
Bonovas, S.1
Filioussi, K.2
Tsavaris, N.3
Sitaras, N.M.4
-
39
-
-
54849131100
-
Statins and cancer: A systematic review and metaanalysis
-
Kuoppala J, Lamminpaa A, Pukkala E. Statins and cancer: a systematic review and metaanalysis. Eur J Cancer. 2008;44:2122-32.
-
(2008)
Eur J Cancer
, vol.44
, pp. 2122-2132
-
-
Kuoppala, J.1
Lamminpaa, A.2
Pukkala, E.3
-
40
-
-
84881491358
-
Statins are associated with a reduced risk of hepatocellular cancer: A systematic review and meta-analysis
-
Singh S, Singh PP, Singh AG, Murad MH, Sanchez W. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology. 2013;144:323-332
-
(2013)
Gastroenterology
, vol.144
, pp. 323-332
-
-
Singh, S.1
Singh, P.P.2
Singh, A.G.3
Murad, M.H.4
Sanchez, W.5
-
41
-
-
28844490054
-
Statins and cancer prevention
-
DOI 10.1038/nrc1751
-
Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM. Statins and cancer prevention. Nat Rev Cancer. 2005;5:930-42. (Pubitemid 41766782)
-
(2005)
Nature Reviews Cancer
, vol.5
, Issue.12
, pp. 930-942
-
-
Demierre, M.-F.1
Higgins, P.D.R.2
Gruber, S.B.3
Hawk, E.4
Lippman, S.M.5
-
42
-
-
84864031678
-
Regular statin and aspirin use in patients with Barrett's oesophagus is associated with a reduced incidence of oesophageal adenocarcinoma
-
Beales IL, Vardi I, Dearman L. Regular statin and aspirin use in patients with Barrett's oesophagus is associated with a reduced incidence of oesophageal adenocarcinoma. Eur J Gastroenterol Hepatol 2012;24(8):917-23.
-
(2012)
Eur J Gastroenterol Hepatol
, vol.24
, Issue.8
, pp. 917-923
-
-
Beales, I.L.1
Vardi, I.2
Dearman, L.3
-
43
-
-
84859386286
-
Use of statin medications and risk of esophageal adenocarcinoma in persons with Barrett's esophagus
-
Kantor ED, Onstad L, Blount PL, Reid BJ, Vaughan TL. Use of statin medications and risk of esophageal adenocarcinoma in persons with Barrett's esophagus. Cancer Epidemiol Biomarkers Prev. 2012;21:456-61.
-
(2012)
Cancer Epidemiol Biomarkers Prev
, vol.21
, pp. 456-461
-
-
Kantor, E.D.1
Onstad, L.2
Blount, P.L.3
Reid, B.J.4
Vaughan, T.L.5
-
44
-
-
80053367221
-
Exposure to statins and risk of common cancers: A series of nested case-control studies
-
Vinogradova Y, Coupland C, Hippisley-Cox J. Exposure to statins and risk of common cancers: a series of nested case-control studies. BMC Cancer. 2011;11:409.
-
(2011)
BMC Cancer
, vol.11
, pp. 409
-
-
Vinogradova, Y.1
Coupland, C.2
Hippisley-Cox, J.3
-
45
-
-
84878135553
-
Statins are associated with reduced risk of esophageal cancer, particularly in patients with Barrett's esophagus: A systematic review and metaanalysis
-
doi:10.1016/ j.cgh.2012.12.036
-
Singh S, Singh AG, Singh PP, Murad MH, Iyer PG. Statins are associated with reduced risk of esophageal cancer, particularly in patients with Barrett's esophagus: a systematic review and metaanalysis. Clin Gastroenterol Hepatol. 2013. doi:10.1016/ j.cgh.2012.12.036.
-
(2013)
Clin Gastroenterol Hepatol.
-
-
Singh, S.1
Singh, A.G.2
Singh, P.P.3
Murad, M.H.4
Iyer, P.G.5
-
46
-
-
4944242891
-
Polyamines and cancer: Old molecules, new understanding
-
DOI 10.1038/nrc1454
-
Gerner EW, Meyskens Jr FL. Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer. 2004;4:781-92. (Pubitemid 39331150)
-
(2004)
Nature Reviews Cancer
, vol.4
, Issue.10
, pp. 781-792
-
-
Gerner, E.W.1
Meyskens Jr., F.L.2
-
47
-
-
0345535621
-
Development of difluoromethylornithine (DFMO) as a chemoprevention agent
-
Meyskens Jr FL, Gerner EW. Development of difluoromethylornithine (DFMO) as a chemoprevention agent. Clin Cancer Res. 1999;5:945-51. (Pubitemid 29233206)
-
(1999)
Clinical Cancer Research
, vol.5
, Issue.5
, pp. 945-951
-
-
Meyskens Jr., F.L.1
Gerner, E.W.2
-
48
-
-
0014323475
-
Amine synthesis in rapidly growing tissues: Ornithine decarboxylase activity in regenerating rat liver, chick embryo, and various tumors
-
Russell D, Snyder SH. Amine synthesis in rapidly growing tissues: ornithine decarboxylase activity in regenerating rat liver, chick embryo, and various tumors. Proc Natl Acad Sci USA. 1968;60:1420-7.
-
(1968)
Proc Natl Acad Sci USA
, vol.60
, pp. 1420-1427
-
-
Russell, D.1
Snyder, S.H.2
-
49
-
-
0023925010
-
Ornithine decarboxylase and polyamine levels in columnar upper gastrointestinal mucosae in patients with Barrett's esophagus
-
Garewal HS, Gerner EW, Sampliner RE, Roe D. Ornithine decarboxylase and polyamine levels in columnar upper gastrointestinal mucosae in patients with Barrett's esophagus. Cancer Res. 1988;48(11):3288-91.
-
(1988)
Cancer Res
, vol.48
, Issue.11
, pp. 3288-3291
-
-
Garewal, H.S.1
Gerner, E.W.2
Sampliner, R.E.3
Roe, D.4
-
50
-
-
0032403096
-
α-Difluoromethylornithine inhibits N-nitrosomethylbenzylamine- induced esophageal carcinogenesis in zinc-deficient rats: Effects on esophageal cell proliferation and apoptosis
-
Fong LY, Pegg AE, Magee PN. Alpha-difluoromethylornithine inhibits N-nitrosomethylbenzylamine-induced esophageal carcinogenesis in zinc-deficient rats: effects on esophageal cell proliferation and apoptosis. Cancer Res. 1998;58:5380-8. (Pubitemid 28551120)
-
(1998)
Cancer Research
, vol.58
, Issue.23
, pp. 5380-5388
-
-
Fong, L.Y.Y.1
Pegg, A.E.2
Magee, P.N.3
-
51
-
-
0028658301
-
Preclinical efficacy evaluation of potential chemopreventive agents in animal carcinogenesis models: Methods and results from the NCI Chemoprevention Drug Development Program
-
Steele VE, Moon RC, Lubet RA, Grubbs CJ, Reddy BS, Wargovich M, et al. Preclinical efficacy evaluation of potential chemopreventive agents in animal carcinogenesis models: methods and results from the NCI Chemoprevention Drug Development Program. J Cell Biochem Suppl. 1994;20:32-54.
-
(1994)
J Cell Biochem Suppl
, vol.20
, pp. 32-54
-
-
Steele, V.E.1
Moon, R.C.2
Lubet, R.A.3
Grubbs, C.J.4
Reddy, B.S.5
Wargovich, M.6
-
52
-
-
84870662091
-
A phase III skin cancer chemoprevention study of DFMO: Long-term follow-up of skin cancer events and toxicity
-
Kreul SM, Havighurst T, Kim K, Mendonça EA, Wood GS, Snow S, et al. A phase III skin cancer chemoprevention study of DFMO: long-term follow-up of skin cancer events and toxicity. Cancer Prev Res (Phila). 2012;5(12):1368-74.
-
(2012)
Cancer Prev Res (Phila)
, vol.5
, Issue.12
, pp. 1368-1374
-
-
Kreul, S.M.1
Havighurst, T.2
Kim, K.3
Mendonça, E.A.4
Wood, G.S.5
Snow, S.6
-
53
-
-
0028358206
-
Gastrointestinal tissue polyamine contents of patients with Barrett's esophagus treated with α-difluoromethylornithine
-
Gerner EW, Garewal HS, Emerson SS, Sampliner RE. Gastrointestinal tissue polyamine contents of patients with Barrett's esophagus treated with alpha-difluoromethylornithine. Cancer Epidemiol Biomarkers Prev. 1994;3(4):325-30. (Pubitemid 24181577)
-
(1994)
Cancer Epidemiology Biomarkers and Prevention
, vol.3
, Issue.4
, pp. 325-330
-
-
Gerner, E.W.1
Garewal, H.S.2
Emerson, S.S.3
Sampliner, R.E.4
-
54
-
-
18044404506
-
Upregulation of ornithine decarboxylase mRNA expression in Barrett's esophagus and Barrett's-associated adenocarcinoma
-
discussion 82
-
Brabender J, Lord RV, Danenberg KD, Metzger R, Schneider PM, Uetake H, et al. Upregulation of ornithine decarboxylase mRNA expression in Barrett's esophagus and Barrett's-associated adenocarcinoma. J Gastrointest Surg. 2001;5:174-81. discussion 82.
-
(2001)
J Gastrointest Surg
, vol.5
, pp. 174-181
-
-
Brabender, J.1
Lord, R.V.2
Danenberg, K.D.3
Metzger, R.4
Schneider, P.M.5
Uetake, H.6
-
55
-
-
79957810567
-
Evaluation of difluoromethylornithine for the chemoprevention of Barrett's esophagus and mucosal dysplasia
-
Sinicrope FA, Broaddus R, Joshi N, Gerner E, Half E, Kirsch I, et al. Evaluation of difluoromethylornithine for the chemoprevention of Barrett's esophagus and mucosal dysplasia. Cancer Prev Res (Phila). 2011;4(6):829-39.
-
(2011)
Cancer Prev Res (Phila)
, vol.4
, Issue.6
, pp. 829-839
-
-
Sinicrope, F.A.1
Broaddus, R.2
Joshi, N.3
Gerner, E.4
Half, E.5
Kirsch, I.6
|